+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma

Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma

Bmc Medical Genomics 12(Suppl 1): 23

While most pediatric sarcomas respond to front-line therapy, some bone sarcomas do not show radiographic response like soft-tissue sarcomas (rhabdomyosarccomas) but do show 90% necrosis. Though, new therapies are urgently needed to improve survival and quality of life in pediatric patients with sarcomas. Complex chromosomal aberrations such as amplifications and deletions of DNA sequences are frequently observed in pediatric sarcomas. Evaluation of copy number variations (CNVs) associated with pediatric sarcoma patients at the time of diagnosis or following therapy offers an opportunity to assess dysregulated molecular targets and signaling pathways that may drive sarcoma development, progression, or relapse. The objective of this study was to utilize publicly available data sets to identify potential predictive biomarkers of chemotherapeutic response in pediatric Osteosarcoma (OS), Rhabdomyosarcoma (RMS) and Ewing's Sarcoma Family of Tumors (ESFTs) based on CNVs following chemotherapy (OS n = 117, RMS n = 64, ESFTs n = 25 tumor biopsies). There were 206 CNV profiles derived from pediatric sarcoma biopsies collected from the public databases TARGET and NCBI-Gene Expression Omnibus (GEO). Through our comparative genomic analyses of OS, RMS, and ESFTs and 22,255 healthy individuals called from the Database of Genomic Variants (DGV), we identified CNVs (amplifications and deletions) pattern of genomic instability in these pediatric sarcomas. By integrating CNVs of Cancer Cell Line Encyclopedia (CCLE) identified in the pool of genes with drug-response data from sarcoma cell lines (n = 27) from Cancer Therapeutics Response Portal (CTRP) Version 2, potential predictive biomarkers of therapeutic response were identified. Genes associated with survival and/recurrence of these sarcomas with statistical significance were found on long arm of chromosome 8 and smaller aberrations were also identified at chromosomes 1q, 12q and x in OS, RMS, and ESFTs. A pool of 63 genes that harbored amplifications and/or deletions were frequently associated with recurrence across OS, RMS, and ESFTs. Correlation analysis of CNVs from CCLE with drug-response data of CTRP in 27 sarcoma cell lines, 33 CNVs out of 63 genes correlated with either sensitivity or resistance to 17 chemotherapies from which actionable CNV signatures such as IGF1R, MYC, MAPK1, ATF1, and MDM2 were identified. These CNV signatures could potentially be used to delineate patient populations that will respond versus those that will not respond to a particular chemotherapy. The large-scale analyses of CNV-drug screening provides a platform to evaluate genetic alterations across aggressive pediatric sarcomas. Additionally, this study provides novel insights into the potential utilization of CNVs as not only prognostic but also as predictive biomarkers of therapeutic response. Information obtained in this study may help guide and prioritize patient-specific therapeutic options in pediatric bone and soft-tissue sarcomas.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066446561

Download citation: RISBibTeXText

PMID: 30704460

DOI: 10.1186/s12920-018-0456-5

Related references

Gene copy number variations in adaptive evolution: The genomic distribution of gene copy number variations revealed by genetic mapping and their adaptive role in an undomesticated species, white spruce (Picea glauca). Molecular Ecology 26(21): 5989-6001, 2017

DNA copy number aberrations associated with the clinicopathological features of colorectal cancers: Identification of genomic biomarkers by array-based comparative genomic hybridization. Oncology Reports 25(6): 1603-1611, 2011

High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. Cancer Genetics 204(3): 129-137, 2011

Genomic copy number variations in glaucomatous neurodegeneration. Molecular Cytogenetics 7(Suppl 1 Proceedings of the International Conference on Human): I33, 2014

Cognitive phenotypes and genomic copy number variations. JAMA 313(20): 2029-2030, 2015

Genomic copy number variations at 17p13.3 and epileptogenesis. Epilepsy Research 89(2-3): 303-309, 2010

Potential Value of Genomic Copy Number Variations in Schizophrenia. Frontiers in Molecular Neuroscience 10: 204, 2017

Genomic characteristics of cattle copy number variations. Bmc Genomics 12: 127, 2011

DNA copy number changes in epithelioid sarcoma and its variants: A comparative genomic hybridization study. Modern Pathology 13(10): 1092-1096, October, 2000

Genomic copy number variations in three Southeast Asian populations. Human Mutation 31(7): 851-857, 2010

DNA copy number changes in alveolar soft part sarcoma: a comparative genomic hybridization study. Modern Pathology 11(3): 227-231, 1998

Analysis of DNA sequence copy number variations by comparative genomic hybridization (CGH). Cancer Genetics and Cytogenetics 84(2): 138-0, 1995

Genomic copy number variations: A breakthrough in our knowledge on schizophrenia etiology?. Neuro Endocrinology Letters 33(2): 183-190, 2012

Analysis of DNA sequence copy number variations by comparative genomic hybridization. Cancer Genetics & Cytogenetics 84(2): 138, 1995

Genomic Organization of TBK1 Copy Number Variations in Glaucoma Patients. Journal of Glaucoma 26(12): 1063-1067, 2017